Wells Fargo & Company Elevation Oncology, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 19,166 shares of ELEV stock, worth $11,307. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,166
Previous 19,146
0.1%
Holding current value
$11,307
Previous $51,000
78.43%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ELEV
# of Institutions
68Shares Held
45.4MCall Options Held
700Put Options Held
27.6K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$3.54 Million0.19% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$2.81 Million0.24% of portfolio
-
Goldman Sachs Group Inc New York, NY3.99MShares$2.35 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.53MShares$2.08 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.07MShares$1.81 Million0.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $13.7M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...